On December 25, the reporter learned from AstraZeneca that Vanovi®, which was jointly developed by the company and Ionis, was officially approved in China to treat adult patients with hereditary transthyroxine amyloidosis polyneuropathy. Eplontrexen sodium is the first and currently the only gene silencing agent approved for ATTRV-PN treatment in China.

On December 25, the reporter learned from AstraZeneca that Vanovi®, which was jointly developed by the company and Ionis, was officially approved in China to treat adult patients with hereditary transthyroxine amyloidosis polyneuropathy. Eplontrexen sodium is the first and currently the only gene silencing agent approved for ATTRV-PN treatment in China.